Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
State Street SPDR Bloomberg 1-3 Month T-Bill ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5. The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYBIL
Market Cap
$29.60B
Sector
HealthFixed Income
52-Week High
$491.22$91.77
52-Week Low
$205.48$91.27
Enterprise Value
$27.56B

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.

Read more on BIL